Skip to main content
. 2023 Oct 26;14:1266067. doi: 10.3389/fneur.2023.1266067

Table 3.

MRI characteristics of GFAP-IgG and MOG-IgG-associated myelitis [n (%)].

Characteristics GFAP-IgG, n = 14 MOG-IgG, n = 24 p-values
Intracranial lesion 11 (78.6%) 21 (87.5%) 0.650
Meningeal enhancement 3/9 (33.3%) 2/11 (18.2%) 0.617
Patchy enhancement 0/9 (0.0%) 6/11 (54.5%) 0.014
Cortical/subcortical 6 (42.9%) 16 (66.7%) 0.187
Medulla oblongata 4 (28.6%) 5 (20.8%) 0.699
Lateral ventricle 4 (28.6%) 4 (16.7%) 0.433
Thalamus 4 (28.6%) 8 (33.3%) 1.000
Pons 4 (28.6%) 11 (45.8%) 0.329
Basal ganglia 2 (14.3%) 8 (33.3%) 0.268
Corpus callosum 1 (7.1%) 2 (8.3%) 1.000
Semiovoid center 1 (7.1%) 1 (4.2%) 1.000
Cerebellum 1 (7.1%) 5 (20.8%) 0.383
Spinal cord MRI
LETM 10/13 (76.9%) 12/21 (57.1%) 0.292
Cervical cord 11/13 (84.6%) 21 (87.5%) 1.000
Thoracic cord 13 (92.9%) 20/23 (87.0%) 1.000
Conus 2/11 (18.2%) 1/21 (4.8%) 0.266
Central gray matter 13 (92.9%) 18 (75.0%) 0.227
“H sign”* 0 (0.0%) 1 (4.2%) 1.000
Multiple lesions 8/12 (66.7%) 10/21 (47.6%) 0.469
Leptomeningeal enhancement 0/6 (0.0%) 1/7 (14.3%) 1.000
Patchy enhancement 4/6 (66.7%) 2/7 (28.6%) 0.286

*Spinal cord MRI T2-hyperintensity is confined to gray matter on axial sequences, forming the “H sign.” LETM, longitudinally extensive transverse myelitis; MRI, magnetic resonance imaging; GFAP, glial fibrillary acidic protein; IgG, immunoglobulin G; MOG, myelin oligodendrocyte glycoprotein.